In this episode, we are joined by Karen Luong, a leader of Husch Blackwell’s Psychedelics & Emerging Therapies practice to discuss current research on psychedelic drugs to treat mental health disorders; the legal implications of that research and potential FDA approval; an overview of potential avenues for rescheduling under Right-to-Try laws; lessons learned from the cannabis industry; and the viability of protections under religious use laws.
